EcoDrugPlus

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSFHEG00000010077
Gene Symbol: PPP3CA
1 Cross references
232 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSFHEG00000009427
Gene Symbol: PTK2
3 Cross references
241 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSFHEG00000001878
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSFHEG00000019688
Gene Symbol: PTPRB
3 Cross references
201 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSFHEG00000013313
Gene Symbol: PTPRB
3 Cross references
193 Possible Orthologues:

Protein-Serine O-Palmitoleoyltransferase Porcupine

Ensembl ID : ENSFHEG00000011220
Gene Symbol: LOC105936610
3 Cross references
197 Possible Orthologues:

Protein-Tyrosine Kinase 2-Beta-Like

Ensembl ID : ENSFHEG00000020358
Gene Symbol: LOC105920313
3 Cross references
196 Possible Orthologues:

Protein-Tyrosine Kinase 6

Ensembl ID : ENSFHEG00000016267
Gene Symbol: LOC105915846
3 Cross references
160 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSFHEG00000006875
Gene Symbol: LOC105925458
3 Cross references
211 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSFHEG00000000158
Gene Symbol: LOC105931131
3 Cross references
265 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSFHEG00000014030
Gene Symbol: LOC105918234
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSFHEG00000011675
Gene Symbol: P2RX3
3 Cross references
192 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).